Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCCAP.L Regulatory News (CCAP)

  • There is currently no data for CCAP

OPD - Charlemagne Capital - Replacement

30 Sep 2016 15:01

RNS Number : 3915L
Charlemagne Capital Limited
30 September 2016
 

 

The following replaces the 'Form 8 (OPD) Charlemagne Capital plc' released on 30 September 2016 at 07.00 under RNS No 2771L.

 

The opening two paragraphs in italics have been included and reference to Form "8" removed.

 

The full amended text is shown below:

 

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

 

Charlemagne Capital has its registered office in Cayman and is not subject to the UK City Code on Takeovers and Mergers (the "Code"). Accordingly the Code does not apply to the Offer by Fiera Capital for Charlemagne Capital and this transaction is not subject to the jurisdiction of, or being regulated by, the UK Panel on Takeovers and Mergers (the "Takeover Panel"). However, Charlemagne Capital and Fiera Capital have agreed, to the extent set out in the Implementation Agreement, that they will conduct themselves and the Offer as if the Offer were subject to the Code.

 

Disclosures made in relation to relevant securities of Charlemagne Capital should be released via a Regulatory Information Service using the headline "Document re: Charlemagne Capital". The headline "Form 8/8.3"should not be used. Any question regarding completion of these forms should be raised with N+1 Singer (tel: +44 (0) 20 7496 3000). Charlemagne Capital Shareholders and persons considering the acquisition or disposal of any interest in Charlemagne Capital Shares are reminded that they are subject to the Disclosure and Transparency Rules made by the UKLA and other applicable regulatory rules regarding transactions in Charlemagne Capital Shares.

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Charlemagne Capital Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Charlemagne Capital Limited

(d) Is the discloser the offeror or the offeree?

OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

27 September 2016

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

Nil

Nil

Nil

(2) Cash-settled derivatives:

 

Nil

Nil

Nil

Nil

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

Nil

Nil

Nil

 

TOTAL:

Nil

Nil

Nil

Nil

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

Interests held by directors of Charlemagne Capital Limited:

 

Director

Shareholding

Percentage holding

James Mellon(1)

55,669,497

19.14

Jayne Sutcliffe(2)

31,708,519

10.90

Jane McAndry

1,266,719

0.44

Lloyd Jones

1,196,938

0.41

Michael Baer

800,000

0.28

Jacob Johan (Jaap) van Duijn

200,000

0.07

Rt Hon Lord Lang of Monkton, PC

100,000

0.03

 

(1) A number of shares included in this holding are held by Galloway Limited, Indigo Securities Limited and Burnbrae Limited, which are each indirectly wholly owned by the trustee of a settlement under which James Mellon has a life interest.

(2) A number of shares included in this holding are held on behalf of the trustees of discretionary trusts, under which Jayne Sutcliffe and members of her family may become beneficiaries.

 

Interests held by directors of subsidiary companies wholly owned by Charlemagne Capital Limited:

 

Director

Shareholding

Percentage holding

Varda Lotan3

4,107,924

1.41

Anderson Whamond4

3,200,000

1.10

Julian Mayo

1,457,864

0.50

Vicky Kydoniefs

371,511

0.13

 

(3) A number of shares included in this holding are held on behalf of the trustees of discretionary trusts, under which Varda Lotan and members of her family may become beneficiaries.

(4) A number of shares included in this holding are held on behalf of the trustees of a pension plan, under which Anderson Whamond and members of his family may become beneficiaries.

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form (Open Positions)

NO

Supplemental Form (SBL)

NO

 

 

Date of disclosure:

30 September 2016

Contact name:

Jane McAndry

Telephone number:

01624 640 216

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEEWGUAABUPQGWU
Date   Source Headline
15th Mar 20167:01 amRNSDividend Declaration
15th Mar 20167:00 amRNSFinal Results
17th Feb 20163:07 pmRNSTR1 - Notification of Major Interest in Shares
19th Jan 20167:00 amRNSTrading Statement
27th Nov 201511:28 amRNSForm 8.3 - Al Noor Hospitals Group PLC
26th Nov 201510:42 amRNSForm 8.3 - Al Noor Hospitals Group PLC
25th Nov 201510:48 amRNSForm 8.3 - Al Noor Hospitals Group PLC
23rd Nov 201511:56 amRNSForm 8.3 - Al Noor Hospitals Group PLC
19th Nov 201510:56 amRNSForm 8.3 -NMC Health PLC
18th Nov 201511:29 amRNSForm 8.3 - Al Noor Hospitals Group PLC
17th Nov 201510:25 amRNSForm 8.3 - NMC Health PLC
17th Nov 20159:42 amRNSForm 8.3 - Al Noor Hospitals Group PLC
17th Nov 20159:35 amRNSForm 8.3 - NMC Health Plc
9th Nov 201511:38 amRNSForm 8.3 - Al Noor Hospitals
4th Nov 20154:32 pmRNSForm 8.3 - NMC Health Plc
28th Oct 201511:34 amRNSForm 8.3 - Al Noor Hospitals
28th Oct 201511:30 amRNSForm 8.3 - NMC Health PLC
16th Oct 201511:27 amRNSHolding(s) in Company
9th Oct 20157:00 amRNSQ3 2015 AUM Update
22nd Sep 20157:01 amRNSDividend Declaration
22nd Sep 20157:00 amRNSHalf Yearly Report
15th Jul 20157:00 amRNSInterim Management Statement
19th Jun 20156:00 pmRNSHolding(s) in Company
19th Jun 201512:17 pmRNSResult of AGM
15th May 20153:05 pmRNSAnnual Report and Notice of AGM
29th Apr 20156:06 pmRNSHolding(s) in Company
10th Apr 20157:00 amRNSQ1 2015 AUM Update
30th Mar 20159:00 amRNSQuadruple Lipper Award Win for Charlemagne Capital
17th Mar 20157:05 amRNSDividend Declaration
17th Mar 20157:00 amRNSFinal Results
13th Jan 20157:00 amRNSTrading Statement
23rd Dec 20144:28 pmRNSDirector/PDMR Shareholding
10th Oct 20147:00 amRNSQ3 2014 AUM Update
18th Sep 201410:38 amRNSDirector/PDMR Shareholding
17th Sep 201411:46 amRNSDirector/PDMR Shareholding
16th Sep 20147:30 amRNSDividend Declaration
16th Sep 20147:00 amRNSHalf Yearly Report
15th Jul 20147:00 amRNSInterim Management Statement
20th Jun 20144:02 pmRNSResult of AGM
19th May 20149:20 amRNSMAGNA MENA FUND REACHES 3 YEAR ANNIVERSARY
14th May 20142:38 pmRNSNotice of AGM
14th May 20147:00 amRNSDirector/PDMR Shareholding
9th May 20148:16 amRNSTriple Lipper Award Win for Charlemagne Capital
28th Apr 20143:27 pmRNSChange to Significant Shareholding
25th Apr 201412:49 pmRNSHolding(s) in Company
25th Apr 201410:30 amRNSHolding(s) in Company
8th Apr 20147:00 amRNSQ1 2014 AUM Update
18th Mar 20147:05 amRNSDividend Declaration
18th Mar 20147:00 amRNSFinal Results
14th Jan 20144:12 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.